Physician profile
Ronald Young
NPI 1295706455
$2,095.36
in general payments reported to CMS, 2019-2025
25 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $118 · 2021: $413 · 2022: $230 · 2023: $365 · 2024: $338 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.24 | 2019-2024 | |
| Astellas Pharma US INC | $292.28 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $229.10 | 2019-2025 | |
| Exeltis, USA INC. | $164.55 | 2021-2025 | Slynd |
| Cumberland Pharmaceuticals, INC. | $159.05 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $107.18 | 2021-2025 | |
| Daiichi Sankyo INC. | $93.89 | 2019-2024 | Injectafer |
| Aspira Women'S Health INC | $82.54 | 2021 | |
| Organon LLC | $75.54 | 2021-2025 | Jada System, Nexplanon |
| Hologic Sales and Service, LLC | $64.71 | 2023-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Pfizer INC. | $61.10 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.77 | 2022 | |
| Biogen, INC. | $49.00 | 2024 | Zurzuvae |
| Applied Medical Resources Corporation | $46.38 | 2023 | Gelpoint V-Path |
| Avion Pharmaceuticals | $39.09 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $36.38 | 2019 | |
| Lupin INC. | $35.85 | 2019-2021 | |
| Millicent US INC | $30.56 | 2025 | Intrarosa, Femlyv |
| Ardelyx, INC. | $29.03 | 2025 | Ibsrela |
| Teleflex LLC | $18.13 | 2024 | Deknatel |
| Convatec INC. | $15.96 | 2019 | |
| Amgen INC. | $15.94 | 2025 | Evenity |
| Merck Sharp & Dohme LLC | $12.85 | 2019 | |
| Allergan, INC. | $12.83 | 2020 | |
| Coopersurgical, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.